Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions

por Vart, Priya, Correa-Rotter, Ricardo, Hou, Fan Fan, Jongs, Niels, Chertow, Glenn M., Langkilde, Anna Maria, McMurray, John J.V., Rossing, Peter, Sjöström, C. David, Stefansson, Bergur V., Toto, Robert D., Douthat, Walter, Escudero, Elizabeth, Isidto, Rey, Khullar, Dinesh, Bajaj, Harpreet S., Wheeler, David C., Heerspink, Hiddo J.L.
Publicado 2022

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

por Wheeler, David C, Stefansson, Bergur V, Batiushin, Mikhail, Bilchenko, Oleksandr, Cherney, David Z I, Chertow, Glenn M, Douthat, Walter, Dwyer, Jamie P, Escudero, Elizabeth, Pecoits-Filho, Roberto, Furuland, Hans, Górriz, José Luis, Greene, Tom, Haller, Hermann, Hou, Fan Fan, Kang, Shin-Wook, Isidto, Rey, Khullar, Dinesh, Mark, Patrick B, McMurray, John J V, Kashihara, Naoki, Nowicki, Michal, Persson, Frederik, Correa-Rotter, Ricardo, Rossing, Peter, Toto, Robert D, Umanath, Kausik, Van Bui, Pham, Wittmann, István, Lindberg, Magnus, Sjöström, C David, Langkilde, Anna Maria, Heerspink, Hiddo J L
Publicado 2020